Tag: Bristol-Myers Squibb Co

Finance

Healthcare Active Movers: Zogenix, Inc. (NASDAQ:ZGNX), Orexigen Therapeutics (NASDAQ:OREX), Merck & Co (NYSE:MRK), Boston Scientific Corporation (NYSE:BSX), Bristol-Myers Squibb (NYSE:BMY)

Zogenix, Inc (NASDAQ:ZGNX) CEO Roger Hawley unloaded 25,078 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $2.10, for a total transaction of $52,663.80. Following the completion of the sale, the chief executive officer now directly owns 1,204,447 shares in the company, valued at approximately $2,529,339. Zogenix, … Continue reading Healthcare Active Movers: Zogenix, Inc. (NASDAQ:ZGNX), Orexigen Therapeutics (NASDAQ:OREX), Merck & Co (NYSE:MRK), Boston Scientific Corporation (NYSE:BSX), Bristol-Myers Squibb (NYSE:BMY)

Richard Atkins
FB Nasdaq FB Facebook
Finance

Healthcare Active Stocks: Johnson & Johnson (NYSE:JNJ), Endo International (NASDAQ:ENDP), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY)

Johnson & Johnson (NYSE: JNJ) has inked a global licensing deal with the privately held Aduro BioTech for developing new therapies to treat prostate cancer. According to the oncology deal, the private company granted Janssen Biotech, a division of Johnson & Johnson, the exclusive license to certain candidates specifically engineered for the treatment of prostate cancer on the basis of Aduro’s proprietary live-attenuated double-deleted (LADD) … Continue reading Healthcare Active Stocks: Johnson & Johnson (NYSE:JNJ), Endo International (NASDAQ:ENDP), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY)

John Bellich
Gilead Sciences GILD NASDAQ:GILD
Finance

Healthcare Losers: Bristol-Myers Squibb (NYSE:BMY), LDR Holding Corp (NASDAQ:LDRH), Vanda Pharmaceuticals (NASDAQ:VNDA), Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Bristol-Myers Squibb Co (NYSE:BMY) and Urban Outfitters (URBN) retreated 6.1 percent and 3.6 percent respectively, after brokers lowered their ratings on these stocks. Weaker-than-expected first-quarter results and dismal second-quarter earnings guidance led Wal-Mart Stores (WMT) to drop 2.4 per cent. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -6.12% in last session and finished the day at $48.93. Traded volume was 28.56million shares in the last … Continue reading Healthcare Losers: Bristol-Myers Squibb (NYSE:BMY), LDR Holding Corp (NASDAQ:LDRH), Vanda Pharmaceuticals (NASDAQ:VNDA), Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Mark DeFrance
Finance

Healthcare Most Active Movers: Bristol-Myers Squibb (NYSE:BMY), Ariad Pharmaceuticals (NASDAQ:ARIA), Avanir Pharmaceuticals (NASDAQ:AVNR), Rexahn Pharmaceuticals (NYSEMKT:RNN)

Zacks restated their neutral rating on shares of Bristol-Myers Squibb Co (NYSE:BMY) in a research note issued to investors on Wednesday. The firm currently has a $52.00 price target on the stock. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -1.14% in last session and finished the day at $49.52. Traded volume was 8.89million shares in the last session and the average volume of the stock … Continue reading Healthcare Most Active Movers: Bristol-Myers Squibb (NYSE:BMY), Ariad Pharmaceuticals (NASDAQ:ARIA), Avanir Pharmaceuticals (NASDAQ:AVNR), Rexahn Pharmaceuticals (NYSEMKT:RNN)

Kevin Long